Last night, Openwave Systems Inc. (NASDAQ: OPWV) did the right thing by rejecting a Harbinger "control offer" that was essentially a "takeunder" rather than a takeover. The offer was worth a whopping $8.30 per share. Unfortunately, the Street had hoped that the old $8.30 was grossly undervaluing the company as the shares yesterday reached $10.37.
The company also announced it was cutting 20% of its workforce and paying out a $100 million dividend; the company only has $334.4 million in cash and equivalents as of March 31, 2007. That sounds like a "we're going at it alone" strategy if there ever was one, and the company is even referring to this as a "stand-alone plan." Back in early May, shares of Openwave were nestled under $8.00.
This rejection of the Harbinger buyout was indeed the right move, but the company should have known better than to wait almost a few weeks. It doesn't take that long to use an abacus to realize that a takeunder is just not going to work. Management is a serious void here, or so it seems. Shares are back all the way down to $8.38 in pre-market trading (9:16 a.m.) or a 19.2% drop.
There are a few companies that could use Openwave as a portfolio company. Once the quarter-to-quarter performance expectations are removed, this company actually offers a substantial platform for almost every aspect of mobile communications and it already has agreements in place with most of the cell and wireless carriers out there.
Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.
Last updated: February 13, 2012: 08:52 AM
Hot Stocks
DailyFinance Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
Benzinga Headlines
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
- Don't Bank on Barclays
TheFlyOnTheWall.com Headlines
- Chesapeake Energy volatility flat at 42 into financial plan
- Gardner Denver shares attractive at current levels, says RBC Capital
- Parkway Properties completes purchase of Phoenix Asset
- Total Q4 results in-line with expectations, says Nomura
- Mattress Firm downgraded to Market Perform from Outperform at Raymond James
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

